An Open-Label, Single-Arm Basket Study of ATG-008 for the Treatment of Patients With Advanced Solid Tumors Harboring NFE2L2, STK11, RICTOR or Other Specific Genetic Alterations
Latest Information Update: 16 Aug 2022
At a glance
- Drugs Onatasertib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms BUNCH
- Sponsors Antengene Corporation
- 07 Aug 2022 Status changed from recruiting to discontinued.
- 12 Apr 2021 According to an Antengene Corporation media release, first patient has been dosed in this trial.
- 12 Apr 2021 Status changed from not yet recruiting to recruiting, according to an Antengene Corporation media release.